NCT04510298View on ClinicalTrials.gov

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions

Schizophrenia

Interventions

DRUG

SP-624

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (2)

92845

Collaborative Neuroscience Research, Garden Grove

08053

Hassman Research Institute, Marlton

All Listed Sponsors

lead

Sirtsei Pharmaceuticals, Inc.

INDUSTRY

NCT04510298 - A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter